Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future?

Dario Siniscalco, Anna Sapone, Alessandra Cirillo, Catia Giordano, Sabatino Maione, Nicola Antonucci, Dario Siniscalco, Anna Sapone, Alessandra Cirillo, Catia Giordano, Sabatino Maione, Nicola Antonucci

Abstract

Autism and autism spectrum disorders (ASDs) are heterogeneous neurodevelopmental disorders. They are enigmatic conditions that have their origins in the interaction of genes and environmental factors. ASDs are characterized by dysfunctions in social interaction and communication skills, in addition to repetitive and stereotypic verbal and nonverbal behaviours. Immune dysfunction has been confirmed with autistic children. There are no defined mechanisms of pathogenesis or curative therapy presently available. Indeed, ASDs are still untreatable. Available treatments for autism can be divided into behavioural, nutritional, and medical approaches, although no defined standard approach exists. Nowadays, stem cell therapy represents the great promise for the future of molecular medicine. Among the stem cell population, mesenchymal stem cells (MSCs) show probably best potential good results in medical research. Due to the particular immune and neural dysregulation observed in ASDs, mesenchymal stem cell transplantation could offer a unique tool to provide better resolution for this disease.

Figures

Figure 1
Figure 1
Paracrine and immunomodulatory effects as possible mechanisms of action of mesenchymal stem cells (MSCs) in autism spectrum disorder (ASD) treatment. In humans, ASDs are associated with immune alterations and pro-inflammatory cytokines (i.e., IL-1β) over-production. These cytokines are able to trigger pro-inflammatory cellular events. Data from in vitro models show that MSCs are able to affect not only T cells, but also other cells of the immune system (i.e., NK cells). Immunoregulatory properties of MSCs are through secretion of large amounts of several bioactive molecules (paracrine activity), that is, PGE-2, IL-10. These molecules cause the inhibition or the unresponsiveness of T-cell mediated responses.

References

    1. Fasano A. Intestine, leaky gut, autism and probiotics. In: Lyndhurst NJ, editor. Cutting Edge Therapies. Barnes & Noble; 2010. pp. 192–198.
    1. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD) Cochrane Database of Systematic Reviews. 2010;8 Article ID CD004677.
    1. Toro R, Konyukh M, Delorme R, et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends in Genetics. 2010;26(8):363–372.
    1. Bradstreet JJ, Smith S, Baral M, Rossignol DA. Biomarker-guided interventions of clinically relevant conditions associated with autism spectrum disorders and attention deficit hyperactivity disorder. Alternative Medicine Review. 2010;15(1):15–32.
    1. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends in Neurosciences. 2006;29(7):349–358.
    1. Toro R, Konyukh M, Delorme R, et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends in Genetics. 2010;26(8):363–372.
    1. El-Fishawy P, State MW. The genetics of autism: key issues, recent findings, and clinical implications. Psychiatric Clinics of North America. 2010;33(1):83–105.
    1. Herbert MR. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Current Opinion in Neurology. 2010;23(2):103–110.
    1. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics. 2004;113(5):e472–e486.
    1. Levy SE, Mandell DS, Schultz RT. Autism. The Lancet. 2009;374(9701):1627–1638.
    1. CDC. Surveillance summaries. Morbidity and Mortality Weekly Report. 2007;56:1–28.
    1. Main PA, Angley MT, Thomas P, O’Doherty CE, Fenech M. Folate and methionine metabolism in autism: a systematic review. American Journal of Clinical Nutrition. 2010;91(6):1598–1620.
    1. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert Review of Neurotherapeutics. 2008;8(4):657–669.
    1. McCracken JT. Safety issues with drug therapies for autism spectrum disorders. Journal of Clinical Psychiatry. 2005;66(supplement 10):32–37.
    1. Tandon M, Pruett JR., Jr. An overview of the use of antidepressants in children and adolescents. Missouri Medicine. 2008;105(1):79–85.
    1. Nevels RM, Dehon EE, Alexander K, Gontkovsky ST. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Experimental and Clinical Psychopharmacology. 2010;18(2):184–201.
    1. Dhossche DM, Shah A, Wing L. Blueprints for the assessment, treatment, and future study of catatonia in autism spectrum disorders. International Review of Neurobiology. 2006;72:267–284.
    1. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Annals of Clinical Psychiatry. 2009;21(4):213–236.
    1. Şenel HG. Parents’ views and experiences about complementary and alternative medicine treatments for their children with autistic spectrum disorder. Journal of Autism and Developmental Disorders. 2010;40(4):494–503.
    1. Wong VC, Sun JG. Randomized controlled trial of acupuncture versus sham acupuncture in autism spectrum disorder. Journal of Alternative and Complementary Medicine. 2010;16(5):545–553.
    1. Filipek PA, Steinberg-Epstein R, Book TM. Intervention for autistic spectrum disorders. NeuroRx. 2006;3(2):207–216.
    1. Vismara LA, Rogers SJ. Behavioral treatments in autism spectrum disorder: what do we know? Annual Review of Clinical Psychology. 2010;6:447–468.
    1. Kasari C, Lawton K. New directions in behavioral treatment of autism spectrum disorders. Current Opinion in Neurology. 2010;23(2):137–143.
    1. Murdock LC, Hobbs JQ. Picture me playing: increasing pretend play dialogue of children with autism spectrum disorders. Journal of Autism and Developmental Disorders. 2011;41:870–878.
    1. Frankel F, Whitham C. Parent-assisted group treatment for friendship problems of children with autism spectrum disorders. Brain Research. 2011;1380:240–245.
    1. Valenti M, Cerbo R, Masedu F, De Caris M, Sorge G. Intensive intervention for children and adolescents with autism in a community setting in Italy: a single-group longitudinal study. Child and Adolescent Psychiatry and Mental Health. 2010;4, article no. 23
    1. Ospina MB, Seida JK, Clark B, et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One. 2008;3(11) Article ID e3755.
    1. Stahmer AC, Schreibman L, Cunningham AB. Toward a technology of treatment individualization for young children with autism spectrum disorders. Brain Research. 2011;1380:229–239.
    1. Coury D. Medical treatment of autism spectrum disorders. Current Opinion in Neurology. 2010;23(2):131–136.
    1. Siniscalco D, Sullo N, Maione S, Rossi F, D’Agostino B. Stem cell therapy: the great promise in lung disease. Therapeutic Advances in Respiratory Disease. 2008;2(3):173–177.
    1. Brooke G, Cook M, Blair C, et al. Therapeutic applications of mesenchymal stromal cells. Seminars in Cell and Developmental Biology. 2007;18(6):846–858.
    1. Arthur A, Zannettino A, Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. Journal of Cellular Physiology. 2009;218(2):237–245.
    1. Chagastelles PC, Nardi NB, Camassola M. Biology and applications of mesenchymal stem cells. Science Progress. 2010;93(2):113–127.
    1. Short B, Brouard N, Occhiodoro-Scott T, Ramakrishnan A, Simmons PJ. Mesenchymal stem cells. Archives of Medical Research. 2003;34(6):565–571.
    1. Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handbook of Experimental Pharmacology. 2006;(174):249–282.
    1. Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Research Reviews. 2006;5(1):91–116.
    1. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.
    1. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. Journal of Cellular Physiology. 2007;211(1):27–35.
    1. Pricola KL, Kuhn NZ, Haleem-Smith H, Song Y, Tuan RS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. Journal of Cellular Biochemistry. 2009;108(3):577–588.
    1. Le Blanc K, Pittenger MF. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36–45.
    1. Beggs KJ, Lyubimov A, Borneman JN, et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplantation. 2006;15(8-9):711–721.
    1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726–736.
    1. Aronin CEP, Tuan RS. Therapeutic potential of the immunomodulatory activities of adult mesenchymal stem cells. Birth Defects Research Part C Embryo Today. 2010;90(1):67–74.
    1. Siniscalco D. Transplantation of human mesenchymal stem cells in the study of neuropathic pain. Methods in Molecular Biology. 2010;617:337–345.
    1. Sotiropoulou PA, Papamichail M. Immune properties of mesenchymal stem cells. Methods in Molecular Biology. 2007;407:225–243.
    1. Newman RE, Yoo D, LeRoux MA, Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflammation and Allergy. 2009;8(2):110–123.
    1. Meyerrose T, Olson S, Pontow S, et al. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Advanced Drug Delivery Reviews. 2010;62(12):1167–1174.
    1. Ksiazek K. A comprehensive review on mesenchymal stem cell growth and senescence. Rejuvenation Research. 2009;12(2):105–116.
    1. Siniscalco D, Giordano C, Galderisi U, et al. Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice. Cellular and Molecular Life Sciences. 2010;67(4):655–669.
    1. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cellular Physiology. 1998;176(1):57–66.
    1. da Silva Meirelles L, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine and Growth Factor Reviews. 2009;20(5-6):419–427.
    1. Giuliani M, Fleury M, Vernochet A, et al. Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One. 2011;6(5) Article ID e19988.
    1. Hoogduijn MJ, Popp F, Verbeek R, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. International Immunopharmacology. 2010;10(12):1496–1500.
    1. Nicola MD, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99(10):3838–3843.
    1. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105(5):2214–2219.
    1. Dazzi F, Marelli-Berg FM. Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. European Journal of Immunology. 2008;38(6):1479–1482.
    1. Ashwood P, Corbett BA, Kantor A, Schulman H, Van de Water J, Amaral DG. In search of cellular immunophenotypes in the blood of children with autism. PLoS One. 2011;6(5) Article ID e19299.
    1. Suzuki K, Matsuzaki H, Iwata K, et al. Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One. 2011;6(5) Article ID e20470.
    1. Gupta S, Samra D, Agrawal S. Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin. Journal of Clinical Immunology. 2010;30(supplement 1):S90–S96.
    1. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain, Behavior, and Immunity. 2010;24(1):64–71.
    1. Oblak AL, Rosene DL, Kemper TL, Bauman ML, Blatt GJ. Altered posterior cingulate cortical cyctoarchitecture, but normal density of neurons and interneurons in the posterior cingulate cortex and fusiform gyrus in autism. Autism Research. 2011;4:200–211.
    1. Whitney ER, Kemper TL, Rosene DL, Bauman ML, Blatt GJ. Density of cerebellar basket and stellate cells in autism: evidence for a late developmental loss of Purkinje cells. Journal of Neuroscience Research. 2009;87(10):2245–2254.
    1. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology. 2001;57(2):245–254.
    1. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: a review and future directions. International Journal of Developmental Neuroscience. 2005;23(2-3):183–187.
    1. Fortin DA, Srivastava T, Soderling TR. Structural modulation of dendritic spines during synaptic plasticity. Neuroscientist. In press.
    1. Sørensen AT, Rogelius N, Lundberg C, Kokaia M. Activity-dependent long-term plasticity of afferent synapses on grafted stem/progenitor cell-derived neurons. Experimental Neurology. 2011;229(2):274–281.
    1. Rodrigues Hell RC, Silva Costa MM, Goes AM, Oliveira AL. Local injection of BDNF producing mesenchymal stem cells increases neuronal survival and synaptic stability following ventral root avulsion. Neurobiology of Disease. 2009;33(2):290–300.
    1. Chang YK, Chen MH, Chiang YH, et al. Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells. Journal of Biomedical Science. 2011;18, article 54(1)
    1. Deng J, Zou ZM, Zhou TL, et al. Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue. Neurological Sciences. 2011;32(4):641–651.
    1. Li L, Jiang J. Regulatory factors of mesenchymal stem cell migration into injured tissues and their signal transduction mechanisms. Frontier Medical. 2011;5:33–39.
    1. Prockop DJ, Gregory CA, Spees JL. One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(1):11917–11923.
    1. Augello A, Kurth TB, De Bari C. Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. European Cells and Materials. 2010;20:121–133.
    1. Momin EN, Mohyeldin A, Zaidi HA, Vela G, Quiñones-Hinojosa A. Mesenchymal stem cells: new approaches for the treatment of neurological diseases. Current Stem Cell Research and Therapy. 2010;5(4):326–344.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe